Technical Analysis for CLYYF - Celyad Oncology Sa

Grade Last Price % Change Price Change
C 0.3930 -27.70% -0.1506
CLYYF closed down 27.7 percent on Tuesday, December 5, 2023, on 59 percent of normal volume. The bears made the stock sink to a new 52-week low.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Gapped Down Weakness 0.00%
New 52 Week Closing Low Bearish -27.70%
Narrow Range Bar Range Contraction -27.70%
New 52 Week Low Weakness -27.70%
Gapped Down Weakness -27.70%
Narrow Range Bar Range Contraction -46.73%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Celyad Oncology Sa Description

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA reagents to reduce expression of one or more defined targets. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.


Classification

Sector: Healthcare
Industry: Biotechnology

Is CLYYF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.7377
52 Week Low 0.393
Average Volume 224
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.0000
Average True Range 0.0000
RSI (14) 0.00
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs) N/A
Chandelier Exit (Short, 3 ATRs) N/A
Upper Bollinger Bands 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0000
MACD Signal Line 0.0000
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.3930
Resistance 3 (R3) 0.3930 0.3930 0.3930
Resistance 2 (R2) 0.3930 0.3930 0.3930 0.3930
Resistance 1 (R1) 0.3930 0.3930 0.3930 0.3930 0.3930
Pivot Point 0.3930 0.3930 0.3930 0.3930 0.3930
Support 1 (S1) 0.3930 0.3930 0.3930 0.3930 0.3930
Support 2 (S2) 0.3930 0.3930 0.3930 0.3930
Support 3 (S3) 0.3930 0.3930 0.3930
Support 4 (S4) 0.3930